Edgestream Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-198,509
| Closed | -$5.57M | – | 1092 |
|
|
2026
Q1 | $5.57M | Buy |
198,509
+63,019
| +47% | +$1.68M | 0.18% | 201 |
|
|
2025
Q4 | $3.37M | Sell |
135,490
-320,613
| -70% | -$8.09M | 0.09% | 387 |
|
|
2025
Q3 | $11.6M | Buy |
456,103
+94,121
| +26% | +$2.32M | 0.34% | 40 |
|
|
2025
Q2 | $8.77M | Buy |
361,982
+19,188
| +6% | +$447K | 0.24% | 107 |
|
|
2025
Q1 | $8.69M | Buy |
342,794
+294,696
| +613% | +$7.71M | 0.29% | 67 |
|
|
2024
Q4 | $1.28M | Sell |
48,098
-164,961
| -77% | -$4.47M | 0.05% | 505 |
|
|
2024
Q3 | $6.17M | Buy |
213,059
+55,092
| +35% | +$1.61M | 0.27% | 89 |
|
|
2024
Q2 | $4.42M | Buy |
157,967
+149,212
| +1,704% | +$4.11M | 0.21% | 153 |
|
|
2024
Q1 | $243K | Buy |
+8,755
| New | +$243K | 0.01% | 756 |
|
|
2023
Q4 | – | Sell |
-16,050
| Closed | -$532K | – | 1007 |
|
|
2023
Q3 | $532K | Sell |
16,050
-1,104
| -6% | -$39K | 0.04% | 583 |
|
|
2023
Q2 | $629K | Sell |
17,154
-24,776
| -59% | -$964K | 0.06% | 478 |
|
|
2023
Q1 | $1.71M | Buy |
41,930
+31,770
| +313% | +$1.37M | 0.19% | 179 |
|
|
2022
Q4 | $521K | Buy |
10,160
+3,118
| +44% | +$149K | 0.06% | 360 |
|
|
2022
Q3 | $308K | Buy |
+7,042
| New | +$342K | 0.02% | 397 |
|
|
2022
Q2 | – | Sell |
-9,384
| Closed | -$486K | – | 607 |
|
|
2022
Q1 | $486K | Sell |
9,384
-58,856
| -86% | -$3.05M | 0.04% | 430 |
|
|
2021
Q4 | $4.03M | Buy |
68,240
+50,236
| +279% | +$2.49M | 0.25% | 122 |
|
|
2021
Q3 | $774K | Buy |
+18,004
| New | +$798K | 0.05% | 353 |
|
|
2020
Q2 | – | Sell |
-51,950
| Closed | -$1.61M | – | 321 |
|
|
2020
Q1 | $1.61M | Sell |
51,950
-38,014
| -42% | -$1.3M | 0.15% | 157 |
|
|
2019
Q4 | $3.34M | Sell |
89,964
-198,371
| -69% | -$7.07M | 0.17% | 157 |
|
|
2019
Q3 | $9.83M | Sell |
288,335
-127,110
| -31% | -$4.62M | 0.94% | 33 |
|
|
2019
Q2 | $17.1M | Sell |
415,445
-69,952
| -14% | -$2.78M | 1.93% | 7 |
|
|
2019
Q1 | $19.6M | Buy |
+485,397
| New | +$19.4M | 2.87% | 2 |
|
|
2014
Q2 | – | Sell |
-33,441
| Closed | -$1.02M | – | 89 |
|
|
2014
Q1 | $1.02M | Buy |
+33,441
| New | +$997K | 1.08% | 25 |
|
Other funds holding PFE
Edgestream Partners's PFE Position: Q2 2026 in Review
Edgestream Partners sold out of Pfizer (PFE) in Q2 2026, closing a stake of 198,509 shares — an estimated $5.57M sold.
Edgestream Partners first reported a position in PFE in Q1 2014 and held it in 23 quarters. The position peaked at $19.6M in Q1 2019. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Edgestream Partners reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
- Edgestream Partners sold 198,509 Pfizer shares in Q2 2026, an estimated $5.57M.
- Edgestream Partners first reported a position in Pfizer in Q1 2014 and held it in 23 quarters.
- Edgestream Partners's Pfizer position peaked at $19.6M in Q1 2019.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.